Selected article for: "failure gastrointestinal dysfunction and gastrointestinal dysfunction"
Author: Niño-Taravilla, Carmen; Espinosa-Vielma, Yazmín P.; Otaola-Arca, Hugo; Poli-Harlowe, Cecilia; Tapia, Lorena I.; Ortiz-Fritz, Paula
Title: Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 Treated with Tocilizumab
  • Cord-id: zimmu3id
  • Document date: 2020_12_4
    • ID: zimmu3id
    Snippet: We describe a case of Pediatric Inflammatory Multisystem Syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in an 8-year-old child. The patient developed multiorgan dysfunction, including mixed shock, cardiac dysfunction with myocarditis, pneumonia, acute kidney failure, and gastrointestinal involvement characterized by inflammation of the wall of the bowel and pancreatitis. After treatment with Tocilizumab and corticoid therapy, he presented clinical improvement and normalization of infla
    Document: We describe a case of Pediatric Inflammatory Multisystem Syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in an 8-year-old child. The patient developed multiorgan dysfunction, including mixed shock, cardiac dysfunction with myocarditis, pneumonia, acute kidney failure, and gastrointestinal involvement characterized by inflammation of the wall of the bowel and pancreatitis. After treatment with Tocilizumab and corticoid therapy, he presented clinical improvement and normalization of inflammatory markers. PIMS-TS is a new disease developed in a small percentage of patients, so a high degree of suspicion is necessary to establish the diagnosis. Supportive care is of paramount importance. The use of Tocilizumab to control the inflammatory response is likely to be beneficial, but the best immunotherapeutic agent has not yet been established. Randomized clinical studies should be run to determine the best treatment.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • abdominal pain and adjuvant treatment: 1
    • abdominal pain and admission second day: 1, 2
    • abdominal pain and macrophage activation: 1, 2, 3, 4
    • abdominal pain and macrophage activation syndrome: 1, 2, 3, 4
    • abdominal pain vomiting and active viral replication: 1
    • abdominal pain vomiting and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain vomiting and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6
    • abdominal pain vomiting and admission second day: 1
    • abdominal pain vomiting and macrophage activation: 1, 2
    • abdominal pain vomiting and macrophage activation syndrome: 1, 2
    • abdominal pain vomiting diarrhea and active viral replication: 1
    • abdominal pain vomiting diarrhea and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain vomiting diarrhea and acute respiratory distress syndrome: 1, 2
    • abdominal pain vomiting diarrhea and admission second day: 1
    • abdominal ultrasound and acute respiratory: 1, 2, 3, 4, 5, 6
    • abdominal ultrasound and acute respiratory distress syndrome: 1, 2, 3
    • active viral replication and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16